Protocol Ledger

NCT06476184 · Phase III · RECRUITING

Utility of Adjusting Chemotherapy Dose & Dosing Schedule With the SALVage Weekly Dose-dense Regimen in Patients With Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete

Interventional Phase III clinical trial protocol NCT06476184 sponsored by ARCAGY/ GINECO GROUP in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-07-30 Enrollment: 250 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06476184
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)250 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06476184
Protocol FieldVerified Registry Value
NCT IdentifierNCT06476184
Consolidated Lead SponsorARCAGY/ GINECO GROUP
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment250 participants (ESTIMATED)
Registered Start Date2024-07-30
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06476184
Hospital Research SiteLocationSite Profile
Institut BergoniéBordeaux, FranceOpen Hospital Dossier ->
Centre François BaclesseCaen, FranceOpen Hospital Dossier ->
Centre Jean PerrinClermont-Ferrand, FranceOpen Hospital Dossier ->
Centre Georges-François LeclercDijon, FranceOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI